<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>GPIIb/IIIa <z:chebi fb="68" ids="48706">antagonists</z:chebi> are expected to have a beneficial effect on <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>, however, the occurrence of <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> has not been as widely investigated </plain></SENT>
<SENT sid="1" pm="."><plain>A rabbit focal thrombotic occlusion model of the middle cerebral artery was established by creating a photochemical reaction between green light and <z:chebi fb="0" ids="52261">Rose Bengal</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Hemorrhagic transformation was common in the area of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Using this model, the effect of a GPIIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi>, ME3277 (low dose, (L); 0.15 mg/kg + 0.125 mg/kg x h, middle dose, (M); 0.3 mg/kg + 0.25 mg/kg x h and high dose, (H); 0.6 mg/kg + 0.5 mg/kg x h), aspirin (20 mg/kg) and <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel (<z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> synthase inhibitor, 1 mg/kg + 2 mg/ kg x h) were evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>Drugs were intravenously administrated 30 minutes after the photochemical reaction for 24 hours </plain></SENT>
<SENT sid="5" pm="."><plain>Aspirin inhibited the ex vivo platelet aggregation induced by <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi> and collagen but not by <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi> (<z:chebi fb="13" ids="16761">ADP</z:chebi>), while <z:chebi fb="199" ids="26708">sodium</z:chebi> ozagrel only inhibited the <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>-induced aggregation </plain></SENT>
<SENT sid="6" pm="."><plain>ME3277 dose-dependently inhibited the platelet aggregation induced by <z:hpo ids='HP_0000001'>all</z:hpo> the inducers (approximately 60% in L, 80% in M, and 90% in H) </plain></SENT>
<SENT sid="7" pm="."><plain>At 24 hours of middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was significantly reduced by aspirin and each dose of ME3277 </plain></SENT>
<SENT sid="8" pm="."><plain>These agents improved neurologic deficits, with ME3277 being more potent than aspirin </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="199" ids="26708">Sodium</z:chebi> ozagrel did not alter the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume nor neurologic deficits </plain></SENT>
<SENT sid="10" pm="."><plain>No drug was found to worsen <z:mp ids='MP_0001914'>hemorrhage</z:mp> volume despite increasing <z:mp ids='MP_0001914'>bleeding</z:mp> time (2-3 fold) in the skin </plain></SENT>
<SENT sid="11" pm="."><plain>In this model, the occluded artery was spontaneously recanalized and re-thrombosed frequently </plain></SENT>
<SENT sid="12" pm="."><plain>One mechanism by which antiplatelet agents reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was inhibition of rethrombosis of the <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>These results suggest that treatment with a GPIIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi> is a useful intervention for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> prolonging dose <z:mp ids='MP_0001914'>bleeding</z:mp> time to 3 times the basal value </plain></SENT>
</text></document>